Existing investor FoxKiser has returned for a $32.5m round that follows the cancer immunotherapy T cell developer's series A two years ago.
WindMIL Therapeutics, a US-based cancer immunotherapy technology spinout from Johns Hopkins University, closed a $32.5m series B round featuring pharmaceutical industry consulting firm FoxKiser on Monday.
The round was led by Qiming Venture Partners USA, an affiliate of the eponymous China-based venture capital firm. Medivate Partners, Domain Associates and Camden Partners Nexus also participated.
WindMIL has created a process of extracting, activating and expanding bone marrow-derived T cells to create what it calls marrow infiltrating lymphocytes (MILs), in order to…
